Baseline pain tolerance, specifically mechanical pain threshold, predicts accelerated biological aging through a mitochondrial‑NLRP3 inflammasome axis in sensory neurons. Individuals with lower mechanical pain thresholds exhibit heightened mitochondrial ROS production, which activates NLRP3 in afferent fibers, driving systemic inflammasome signaling and epigenetic age advancement. This link is independent of chronic pain diagnoses and reflects a physiological state of somatosensory aging that precedes clinical pathology.

Rationale

• Aging alters peripheral nociceptor function: Aδ‑fiber loss raises heat pain thresholds while mechanical sensitivity often declines earlier [3][4].
• Preclinical models show age‑dependent increases in mechanical hypersensitivity linked to neuroinflammation and mitochondrial dysfunction [5].
• High‑impact chronic pain associates with accelerated DNAmAge, PhenoAge, and GrimAge, suggesting that sustained nociceptive stress can imprint epigenetic aging [2].
• Yet baseline pain tolerance alone does not correlate with epigenetic clocks in healthy cohorts, possibly because most studies aggregate modalities or ignore mitochondrial‑inflammasome coupling.

We propose that mechanical pain threshold serves as a readout of sensory neuron mitochondrial ROS, which when excess triggers NLRP3 inflammasome activation, releasing IL‑1β and IL‑18 into circulation. These cytokines promote inflammaging, accelerate DNA methylation drift, and thereby shift biological age forward.

Testable Predictions

1. Cross‑sectional: In a cohort of adults aged 30‑80, lower mechanical pain threshold (measured with von Frey filaments) will correlate with higher mitochondrial ROS in isolated PBMCs (MitoSOX fluorescence) and elevated serum NLRP3‑dependent cytokines (IL‑1β, IL-18) after adjusting for age, sex, BMI, and comorbidities.
2. Longitudinal: Baseline mechanical pain threshold will predict change in epigenetic age (PhenoAgeGrim) over 24 months, independent of baseline epigenetic age and incident chronic pain diagnoses.
3. Mechanistic blockade: Pharmacological inhibition of NLRP3 (MCC950) or mitochondrial antioxidant treatment (MitoQ) in a subset will attenuate the relationship between low pain threshold and cytokine rise, demonstrating causality.
4. Specificity: Heat pain threshold and pressure pain tolerance will show weaker or no association with mitochondrial ROS/NLRP3 markers, underscoring modality selectivity.

Experimental Approach

• Recruit 300 participants, stratify by decade of life.
• Quantify mechanical pain threshold (baseline force detecting pinprick), heat pain threshold (thermal stimulator), and pressure pain tolerance (handheld algometer).
• Collect blood for PBMC mitochondrial ROS assay, plasma IL‑1β/IL‑18, and DNA methylation array (for PhenoAge, GrimAge).
• At 2‑year follow‑up, repeat epigenetic clocks and pain testing.
• Subset of 40 participants randomized to MitoQ, MCC950, or placebo for 12 weeks; intermediate pain and biomarker measures taken at baseline, 6, and 12 weeks.

Potential Impact

If validated, a simple 10‑minute mechanical pain test could serve as a functional proxy for inflammasome‑driven aging, complementing or outperforming current molecular clocks in populations where blood‑based assays are impractical. It would also highlight sensory neuron mitochondria as a therapeutic target for extending healthspan.

Falsifiability

Failure to observe any of the predicted associations—particularly the longitudinal prediction that baseline mechanical pain threshold forecasts epigenetic age change after controlling for confounders—would refute the hypothesis. Similarly, if mitochondrial ROS or NLRP3 inhibition does not modify the pain‑cytokine link, the proposed mechanistic pathway would be unsupported.